Day 2Tuesday, 19 March 2024

Location: Room 111

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

Location: Room 111

Join expert panelists as they navigate the complexities of neuroscience and delve into the innovative advancements and breakthroughs in neurological therapies. Discover opportunities with the potential to revolutionize the way we understand and address neurological challenges and get a glimpse into transformative therapies that lie ahead. 

Location: Exhibit Hall Stage

BioProcess Insider (a BioProcess International publication) editorial team sits down with a select panel of experts to reflect on how the quarterly movements of the wider pharma industry are affecting the bio services space. We look at how global events, deal making, and regulatory and tech advancements are determining the factors driving or squeezing production, while also finding time to focus on developments within a key area of the industry.

Location: Exhibit Hall Stage

Venture debt is a very useful funding instrument for innovative, VC backed companies, but its role in Europe is still somewhat limited.

The session aims to raise awareness about this form of funding and demonstrate how the European Investment Bank, the leading venture debt player in Europe, supports innovative life science companies and how borrowers benefit from this form of funding.

Location: Exhibit Hall Stage

During this session, we will dive into the Paris Region Life Sciences ecosystem and explore how startups can benefit from all its assets. From lab bench to industrialization, we will unveil the thriving journey of a startup inside the #1 European Life Sciences ecosystem with a use case in oncology and bioproduction.

Location: Room 112

What green and red flags do pharmaceutical companies look for from a commercial perspective when evaluating an early-stage biotech company for a potential deal or investment? This is a must for early-stage biotech leaders – learn what can be done as you head toward key milestones to make a deal an easy decision for a commercially-minded partner.

Location: Room 111

This ever-popular session takes a deep dive into the current state of the life sciences industry with the expertise of today’s leading pharma dealmakers and venture investors. Join this engaging discussion to learn how to navigate the current climate of the biotech industry.

Location: Room 111

Women, on average, spend 25% more time in poor health than men. "Closing the Women's Health Gap: A $1 Trillion Opportunity to Improve Lives and Economies," a report published by the McKinsey Health Institute in collaboration with the World Economic Forum Center for Health and Healthcare, redefines Women’s Health and explores the root causes driving this discrepancy and outlines the actions needed to address the shortcomings that limit the ability of many women to live to their full potential. Closing the gender health gap could reduce the time women spend in poor health by almost two-thirds and add up to $1 trillion to the economy annually by 2040, the report says. It could also lead to an additional seven healthy days for every woman each year, or more than 500 days over a woman's lifetime. For every $1 invested in women's health, ~$3 is projected in economic growth, generating the equivalent impact of 137 million women accessing full-time positions by 2040, the research finds.

The session will entail a 10-minute presentation of the “Closing the Women’s Health Gap” report findings, followed by a panel discussion with different stakeholders of the HC ecosystem. Attendees will hear about the most pressing challenges in addressing the women’s health gap, explore the most promising opportunities that biopharma executives can action against, and learn from panelists’ experiences in embedding women’s health into their organizations and operations.

Location: Exhibit hall stage

In the dynamic landscape of drug development innovation, the synergy between biotechs, research partners, and innovative funding models has emerged as a driving force. This symposium explores the intricate relationships and collaborative efforts that are reshaping the future of drug development. Through insightful discussions and expert insights, participants will gain a deeper understanding of how these entities interact, leverage each other's strengths, and propel groundbreaking discoveries forward. Join us as we delve into how to revolutionize the drug development ecosystem where scientific advancements, entrepreneurial spirit, and strategic financing converge will shape a better tomorrow.

Location: Exhibit hall stage

How are you adjusting to the evolving landscape where Life Sciences & Health professionals increasingly prefer to work where they live? The industry has long grappled with talent shortages, but the post-pandemic era has accelerated the need for companies to rethink their approach.

In the past, companies held the allure, drawing talent to their locations. Now, the paradigm has shifted. It's talent that dictates the gravitational pull, not companies. Talent is the new gravity.

What implications does this shift have for your company's growth and its ability to attract top-tier talent? What lessons should we learn from this new reality?

Join a panel of industry frontrunners from Barcelona to explore how they're navigating this new landscape. Discover their strategies for attracting, developing, and retaining talent successfully. Remember, exceptional talent is the cornerstone of exceptional companies—don't risk falling behind.

Location: Room 112

From winning the startup pitch competition in 2017, forgoing a photoshoot opportunity with Messi, to secure funding, and debuting with Nike, join this session to delve into the evolution of Peptomyc. Hear about their entrepreneurial journey, how they have navigated the dynamic startup landscape and the challenges, triumphs and lessons learnt along the way. Further, understand from a VC perspective why Peptomyc shone bright and takeaway tips on how to drive a startup to success.

Location: Room 112

The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.

Participating Companies:

Convert Pharmaceuticals

Elastrin Therapeutics Limited

Lovaltech

Mabswitch Inc

Nanological

Scarlet Therapeutics Ltd

Tabrix

The Blue Box Biomedical Solutions

Location: Room 133/134

EG 427 is the second company to bring a non-replicating HSV-1 vector into clinical development with an IND filling with the FDA in early 2024.
Our unique platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows either for long-term gene therapy, or all-in-one gene editing approaches.

Location: EBD booth

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

Sustainability Focus Area: Social Responsibility

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.